Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7345-7349

  Abdelgawad, Iman Attia ^a   Mossallam, Ghada Ibrahim ^a   Radwan, Noha Hassan ^a   Elzawahry, Heba Mohammed ^a   Elhifnawy, Niveen Mostafa ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Diagnosis; Egypt; ELISA; Glypican3; HCC; RT PCR

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COMPARATIVE STUDY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYPICANS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893376655     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7345     Document Type: Article

References (26)

1. Anwar WA, Khaled HM, Amra HA, et al (2008). Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res, 659, 176-84.
2. El-Shenawy S, El Sabawi M, Sheble N, et al (2012). Diagnotic Role of serum Glypican-3 as a tumor marker for hepatocellular carcinoma. Nature Sci, 10, 32-8.
3. Filmus J, Capurro M (2004). Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diag, 8, 207-12.
4. Gomaa A, Hendy O, Aboraia G, et al (2012). The diagnostic Value of Peripheral blood Glypican-3 in patients with hepatocellular carcinoma. World J Med Sci, 7, 105-12.
5. Hippo Y, Watanabe K, Watanabe A, et al (2004). Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res, 64, 2418-23.
6. Iglesias V, Centeno G, Pascucceli H, et al (2008). Expression pattern of glypican-3 (GPC-3) during human embryonic and fetal development. Histol Histopathol, 23, 1333-40.
7. Inoue K, Sugiyama H, Ogawa H, et al (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 3071-9.
8. Jackbovic B, Jothy S (2007). Glypican-3 from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol, 82, 184-9.
9. Kandil D, Cooper K (2009). Glypican-3: A novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 16, 125-9.
10. Lehman EM, Wilson ML (2009). Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systemic review and meta-analysis. Int J Cancer, 124, 690-7.
11. Li BD, Zhao QC, Zhu YT, et al (2006). Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi, 44, 458-62.
12. Liu H, Li P, Zhai Y, et al (2010). Diagnostic value of Glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol, 16, 4410-5.
13. Nakatsura T, Nishimura Y (2005). Usefulness of the novel oncofetal antigen, Glypican 3, for diagnosis of hepatocellular carcinoma and melanoma. Bio Drugs, 19, 71-7.
14. Nakatsura T, Yoshitake Y, Senju S, et al (2003). Glypican 3: Overexpressed specially in human hepatocellular carcinoma., is a novel tumor marker. Biochem Biophys Res Commun, 306, 16-25.
15. National Cancer Institute Cairo (2010). Cancer registry 2002-2007. Website: www.nci.edu.eg.data.
16. Nishimura Y, Nakatsura T, Senju S (2008). Usefulness of a novel oncofetal antigen, Glypican 3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi, 31, 383-91.
17. Qiao SS, Cui Z, Gong L, et al (2011). Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepato-Gastroenterol, 58, 1718-24.
18. Shafizadeh N, Ferrel P, Karkar S (2008). Utility and limitation of Glypican-3 expression for the of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol, 21, 1011-8.
19. Sung YK, Hwang SY, Park MK et al (2003). Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci, 94, 259-62.
20. Suriawinata A, Thung SN (2010). Molecular signature of early hepatocellular carcinoma. Oncol, 78, 36-9.
21. Tangkijvanich P, Chanmer T, Komtong S, et al (2010). Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol, 25, 129-37.
22. Trerotoli P, Fransvea E, Angelotti U et al (2009).Tissue expression of squamous cellular carcinoma antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 8, 29.
23. Yan D, He Q, Chen Y, et al (2011). Detection of a-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal, 25, 113-7.
24. Yasuda E, Kumada T, Toyoda H, et al (2010). Evaluation for clinical utility of GPC-3, measured by a commericially available ELISA kit with GPC-3 antibody, as a serological and histological marker for HCC. Hepatol Res, 40, 477-85.
25. Youssef M, El-Sharkawy S, Abbas N, et al (2010). Clinical utility of Glypican-3 in hepatocellular carcinoma. Int J Integr Biol, 10, 41-7.
26. Zakhary N, Khodeer S, Ezzat H, et al (2012). Impact of PIVKAII in diagnosis of hepatocellular carcinoma. International Conference on Ecological Environmental and Biology Sciences, ICEEBS, Jan. 7-8 Dubai.